DEXYANE MED
Soothing repair cream
The DEXYANE MeD medical device treats and limits the recurrence of atopic eczema, contact eczema and chronic hand eczema lesions. This soothing repair cream can be applied directly to eczema lesions. DEXYANE MeD is used alone, in combination or as a relay of dermocorticoids (does not contain cortisone).
- Legal Notice
-
*Dexyane MeD soothing repair cream is a medical device, a regulated healthcare product bearing the CE mark. Read instructions carefully before use. Do not use on pregnant or breast-feeding women, on mucous membranes or on the diaper area of children. Avoid direct contact with eyes. From 3 months of age. Ask your pharmacist for more information. Manufacturer: Pierre Fabre Medical Devices. Updated : April 2022.DEXY
-
For whom?From 3 monthsFamily
-
Price100 ml17,50€30 ml12,50€
-
TextureBandage effect.Cortisone-free.
Patient relations
-
Application tips
Treatment: 2 applications a day, alone or in combination, on inflammatory lesions (face, body, hands).
Maintenance: 2 applications a day on affected areas.
Not to be applied to bottom area in children aged 3 months to 6 years.
Due to a lack of data, do not use when pregnant or breastfeeding.
-
In combination with the following treatments
Dermocorticoids.Topical calcineurin inhibitors.
Ingredients
Active ingredients:
Restores the altered hydrolipidic film and corrects dryness thanks to the combination of 20%, shea butter - triglycerides and Hydroxydecine®.
Formula details:
Click on an ingredient type to highlight it in the list
Clinical results and publications
Efficacy results
In combination, it accelerates the effectiveness of dermocorticoids on moderate to severe lesions (2).
SCORAD at D7, when used alone (1).
Flare-up rate at D15, in relay of dermocorticoids (2).
Pain at D15, when used alone (3).
Tolerance results
Tolerance only:
Excellent tolerance in 97% of atopic patients, from babies to adults (1).
Good to excellent tolerance on chronic hand eczema lesions (3).
Tolerance in combination with other treatments:
Very good to excellent in 100% of subjects, in combination with a dermocorticoid (2).
Links to clinical results
Legal Notice
(1) Clinical safety and efficacy study. Methodology: open study on 61 subjects (20 adults, 22 children, 19 babies) with mild to moderate atopic eczema; application of Dexyane MeD 2 times/day alone directly on the lesions for 22 days. Primary tolerance criterion: evaluation of local tolerance (rated from 0 to 5) at D22 by the investigator. Results: Tolerance: excellent in 97% of patients (11). Only 8 patients (9.8%) reported moderate and reversible signs of discomfort. Secondary efficacy criteria: i/ Measurement of SCORAD index
after 1 day, 1 week and 3 weeks. ii/ PGA (Patient global assessment) measurement on the severity of eczema at D8, D15 and D22 (scale from 0=worst to 4=full resolution). Results:
i/ Significant decrease in Scorad Index of 23% after 1 week compared to day 1 (p<0.001), 51% after 3 weeks (p<0.001).
ii/ 75% of patients notice an improvement of their eczema after 3 weeks. (RV4421A2013428,22/02/2016).
(2) Clinical study of safety and efficacy in combination with a medium-activity dermocorticoid and after discontinuation of treatment. Methodology: randomized, open-label, superiority, intraindividual study on 54 adults with atopic eczema on the arms and/or popliteal fossae (moderate to severe lesions), application of Dexyane Med twice daily in combination with a dermocorticoid on one limb versus dermocorticoid alone on the other limb, for 10 days. Primary criterion: assessment of L-SCORAD change (from 0 to 18) at D1 and D3; Result: D1 (10.4 without Dexyane Med, 10.2 with Dexyane Med); D3 (8.9 versus 7.7), significant improvement.(RV4421A2013147; 04/03/2016; 91-92).
(3) Clinical safety and efficacy study. Methodology: open study on 40 adults with chronic hand eczema (mild to moderate lesions), application of Dexyane Med twice daily alone directly on the lesions for 22 days. Primary tolerance criterion: evaluation of local tolerance (from 1 to 5) at D22 by the investigator. Secondary efficacy criterion: Self-assessment of pain intensity (from 0 to 10) at D1, D8, D15 and D22. Results: -Tolerance: excellent (70%), very good (17.5%), good (12.5%); -Pain: D1: 4.2; D8: 1.2 (-73%); D15: 0.8 (-81%); D22: 0.9 (-78%) (RV4421A2013149; 02/29/2016; 111-113, 142).
Illustrative photographs
Day 1
Day 22
Discover the range
Contact us
Would you like to meet a sales representative?
Our medical sales representatives come to your workplace to answer all your questions about our brands and products.
The product concerned may not be available in your country. Please contact your medical sales representative for further information.
Have you noticed any side effects?
The safety and well-being of your patients is our priority. If you notice an unlisted adverse reaction to one of our products, please contact us without delay. We look forward to hearing from you!
Our commitments
Made in France
Product manufactured in our factories in France.
Conscious Care
Pierre Fabre Laboratories brands, including Ducray Dermatological Laboratories, have joined forces and collectively created Conscious Care: a dermo-cosmetic of the future that acts conscientiously towards its entire ecosystem.
Supporting associations
Ducray Dermatological Laboratories support 14 patient associations around the world, with the objective of sharing information on pathologies to improve their management.
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.